• Raised $3.25 million via a placement of 36,111,112 shares
• Placement was well supported by existing and new investors
• Funds will be used for new device manufacturing, marketing, and commercial expansion

Cardiex Limited (ASX: CDX) has announced the completion of a capital raising via a placement of 36,111,112 fully paid ordinary shares to institutional and sophisticated investors, raising $3.25 million (before costs). The new shares were issued at an offer price of $0.09 per share, representing a 9.1% discount to the last closing price and a 9.3% discount to the 15-day VWAP. Participants in the Placement will also receive one free attaching listed option for every new share received, with the options being under the existing class CDXOA.ASX, exercisable at $0.20 and expiring on or before 30 November 2025. The Placement was well supported by existing institutional shareholders as well as a range of new and existing sophisticated investors from both Australia and the USA. Cardiex Directors and C2 Ventures Pty Limited, the Company's largest shareholder, will also participate in the Placement, subject to shareholder approval. Funds raised from the Offer will largely be used for new device manufacturing, marketing and sales activities, and for commercial expansion, including scaling up supply chain operations ahead of the January 2025 US market launch of the CONNEQT Pulse device.